18F-Fluciclovine (18F-FACBC) PET/CT or PET/MRI in gliomas/glioblastomas

Albano, Domenico; Tomasini, Davide; Bonù, Marco Lorenzo; Giubbini, Raffaele; Bertagna, Francesco

doi:10.1007/s12149-019-01426-w

Cited by 27 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 F-fluorodeoxyglucose (FDG) is the most common PET tracer, as it is involved in the glycolysis. Other radio-labelled amino acids or ligands could also be developed for brain tumor diagnosis [15,16]. FDG still contributed around 98% in PET examination.…”

Section: Introductionmentioning

confidence: 99%

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET

et al. 2021

View full text Add to dashboard Cite

Background Non-invasive diagnosis of IDH1 mutation for gliomas has great clinical significance, and PET has natural advantage to detect metabolism, as IDH mutated gliomas share lower glucose consumption. Methods Clinical data of patients with gliomas and 18F-FDG PET were retrospectively reviewed. Receiver operating characteristic curve (ROC) analysis was conducted, and standard uptake value (SUV) was estimated in combination with grades or IDH1 mutation. The glucose consumption was investigated with U251 cells expressing wild-type or mutated IDH1 by glucose assay. Quantification of glucose was determined by HPLC in clinical tissues. Meanwhile, bioinformatics and western blot were applied to analyze the expression level of metabolic enzymes (e.g. HK1, PKM2, PC) in gliomas. Results Seventy-one glioma cases were enrolled, including 30 carrying IDH1 mutation. The sensitivity and specificity dependent on SUVmax (3.85) predicting IDH1 mutation reached 73.2 and 86.7%, respectively. The sensitivity and specificity of differentiating grades by SUVmax (3.1) were 92.3 and 64.4%, respectively. Glucose consumption of U251 IDH1 mutant cells (0.209 ± 0.0472 mg/ml) was obviously lower than IDH1wild-type cells (0.978 ± 0.0773 mg/ml, P = 0.0001) and astrocyte controls (0.335 ± 0.0592 mg/ml, P = 0.0451). Meanwhile, the glucose quantity in IDH1mutant glioma samples were significantly lower than those in IDH1 wild-type tissues (1.033 ± 1.19608 vs 6.361 ± 4.3909 mg/g, P = 0.0051). Silico analysis and western blot confirmed that HK1 and PKM2 in IDH1 wild-type gliomas were significantly higher than in IDH1 mutant group, while PC was significantly higher in IDH1 mutant gliomas. Conclusion SUVmax on PET can predict IDH1 mutation with adequate sensitivity and specificity, as is supported by reduced glucose consumption in IDH1 mutant gliomas.

show abstract

Section: Introductionmentioning

confidence: 99%

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET

et al. 2021

View full text Add to dashboard Cite

show abstract

“…An emerging amino acid PET tracer in pediatrics [ 18 F] fluciclovine PET, also known as Axumin PET, is an FDA-approved tracer for imaging metastatic prostate cancer, but it is also showing promising results in neuro-oncology. 29,[35][36][37][38] It has lower background uptake compared with 11 C-MET and is transported by both L-type amino acid transporter 1 and system alanine-serinecysteine amino acid transporter-2 into the cell. Upcoming trials in pediatric brain tumors will elucidate the role and applications of this tracer in clinical neuro-oncology.…”

Section: Pet/mr Imaging In Pediatric Neuro-oncologymentioning

confidence: 99%

PET/MRI in Pediatric Neuroimaging: Primer for Clinical Practice

Pedersen

Aboian

McConathy

et al. 2022

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

Modern pediatric imaging seeks to provide not only exceptional anatomic detail but also physiologic and metabolic information of the pathology in question with as little radiation penalty as possible. Hybrid PET/MR imaging combines exquisite softtissue information obtained by MR imaging with functional information provided by PET, including metabolic markers, receptor binding, perfusion, and neurotransmitter release data. In pediatric neuro-oncology, PET/MR imaging is, in many ways, ideal for follow-up compared with PET/CT, given the superiority of MR imaging in neuroimaging compared with CT and the lower radiation dose, which is relevant in serial imaging and long-term follow-up of pediatric patients. In addition, although MR imaging is the main imaging technique for the evaluation of spinal pathology, PET/MR imaging may provide useful information in several clinical scenarios, including tumor staging and follow-up, treatment response assessment of spinal malignancies, and vertebral osteomyelitis. This review article covers neuropediatric applications of PET/MR imaging in addition to considerations regarding radiopharmaceuticals, imaging protocols, and current challenges to clinical implementation. ABBREVIATIONS: DOPA ¼ dioxyphenylalanine; DOTATATE ¼ [tetrazetan-D-Phe1,Tyr3]-octreotate; FET ¼ fluoroethyltyrosine; mFBG ¼ meta-fluorobenzylguanidine; MIBG ¼ metaiodobenzylguanidine; LCH ¼ Langerhans cell histiocytosis; max ¼ maximum; MET ¼ methionine; SUV ¼ standard uptake value S erial imaging and radiation dose reduction should remain balanced in pediatric imaging. Repeat PET/CTs, especially in pediatric neuro-oncology, result in a considerable cumulative radiation dose and may increase the risk of secondary cancer. [1][2][3] The risk of radiation-induced malignancy is increased at exposures of .50-100 mSv. 2 A retrospective review of 78 pediatric patients found that the average cumulative dose from PET/CT during a 5-year period amounted to 78.9 mSV. 3 Meanwhile, reduction in the cumulative dose by PET/MR imaging has been reported to be as high as 50%-70% in pediatric lymphoma. [4][5][6] Further dose reduction may be achieved by lowering radiopharmaceutical doses with artificial intelligence-based algorithms, which is an area of active research and product development. 7,8

show abstract

“…Radiolabeling of poly ADP ribose polymerase (PARP) inhibitors is gaining interest with numerous preclinical studies and an ongoing clinical trial in GB patients using [ 18 F]-FluorThanatrace ([ 18 F]F-TT)-PET/CT (NCT04221061) [36,[39][40][41][42][43]. The first clinical results of [ 18 F]-Fluciclovine ([ 18 F]F-ACBC) for GB imaging were promising and radiolabelling of receptor tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) pathway inhibitors has also shown potential [44][45][46][47][48][49][50][51]. It is noted that PET imaging using the deoxycytidine kinase substrate [ 18 F]F-clofarabin has been shown to be a good imaging tool to localise and quantify responses in GB patients undergoing immunotherapy [52].…”

Section: Established and Emerging Pet/spect Radiopharmaceuticals In N...mentioning

confidence: 99%

A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma

Bolcaen¹,

Kleynhans²,

Nair³

et al. 2021

Theranostics

View full text Add to dashboard Cite

Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma (GB) remains a challenge. The current survival rate of GB averages one year, even with an optimal standard of care. However, the future promises efficient patient-tailored treatments, including targeted radionuclide therapy (TRT). Advances in radiopharmaceutical development have unlocked the possibility to assess disease at the molecular level allowing individual diagnosis. This leads to the possibility of choosing a tailored, targeted approach for therapeutic modalities. Therapeutic modalities based on radiopharmaceuticals are an exciting development with great potential to promote a personalised approach to medicine. However, an effective targeted radionuclide therapy (TRT) for the treatment of GB entails caveats and requisites. This review provides an overview of existing nuclear imaging and TRT strategies for GB. A critical discussion of the optimal characteristics for new GB targeting therapeutic radiopharmaceuticals and clinical indications are provided. Considerations for target selection are discussed, i.e. specific presence of the target, expression level and pharmacological access to the target, with particular attention to blood-brain barrier crossing. An overview of the most promising radionuclides is given along with a validation of the relevant radiopharmaceuticals and theranostic agents (based on small molecules, peptides and monoclonal antibodies). Moreover, toxicity issues and safety pharmacology aspects will be presented, both in general and for the brain in particular.

show abstract

18F-Fluciclovine (18F-FACBC) PET/CT or PET/MRI in gliomas/glioblastomas

Cited by 27 publications

References 18 publications

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET

PET/MRI in Pediatric Neuroimaging: Primer for Clinical Practice

A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma

Contact Info

Product

Resources

About